多发性骨髓瘤中的癌症免疫编辑与免疫失调
该综述阐述免疫系统与恶性浆细胞在多发性骨髓瘤各阶段的相互作用,包括意义未明单克隆丙种球蛋白病和冒烟型骨髓瘤。免疫系统早期可清除恶性浆细胞或诱导其功能性休眠,但恶性浆细胞最终逃逸免疫清除并进展为活动性骨髓瘤。骨髓免疫细胞除抗骨髓瘤免疫外还支持浆细胞存活,免疫系统像变阻器一样精细调节休眠与疾病进展的平衡。
要点
- 免疫系统在浆细胞病早期可清除恶性浆细胞或诱导功能性休眠。
- 恶性浆细胞最终逃逸免疫清除,进展为活动性多发性骨髓瘤。
- 骨髓免疫细胞与非造血基质细胞共同支持正常和恶性浆细胞存活。
核心结论
- 免疫系统作为变阻器精细调节浆细胞病中休眠与疾病进展的平衡。
- 深入理解癌症免疫编辑过程可为浆细胞病免疫病理和多发性骨髓瘤免疫治疗提供重要见解。
研究设计与样本
- 综述,检索范围未在原文中报告。
主要发现
- 免疫系统在早期可有效清除恶性浆细胞或至少诱导功能性休眠。
- 恶性浆细胞最终逃逸免疫清除,进展为活动性多发性骨髓瘤。
- 在活动性多发性骨髓瘤中,功能失调的效应淋巴细胞、肿瘤驯化的免疫抑制细胞和可溶性介质协同构成抗骨髓瘤免疫的屏障。
- 骨髓免疫细胞与非造血基质细胞共同支持骨髓微环境中正常和恶性浆细胞的存活。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Avoiding immune destruction is a hallmark of cancer. Over the past few years, significant advances have been made in understanding immune dysfunction and immunosuppression in multiple myeloma (MM), and various immunotherapeutic approaches have delivered improved clinical responses. However, it is still challenging to completely eliminate malignant plasma cells (PCs) and achieve complete cure. The interplay between the immune system and malignant PCs is implicated throughout all stages of PC dyscrasias, including asymptomatic states called monoclonal gammopathy of undetermined significance and smoldering myeloma. Although the immune system effectively eliminates malignant PCs, or at least induces functional dormancy at early stages, malignant PCs eventually evade immune elimination, leading to progression to active MM, in which dysfunctional effector lymphocytes, tumor-educated immunosuppressive cells, and soluble mediators coordinately act as a barrier for antimyeloma immunity. An in-depth understanding of this dynamic process, called cancer immunoediting, will provide important insights into the immunopathology of PC dyscrasias and MM immunotherapy. Moreover, a growing body of evidence suggests that, together with nonhematopoietic stromal cells, bone marrow (BM) immune cells with unique functions support the survival of normal and malignant PCs in the BM niche, highlighting the diverse roles of immune cells beyond antimyeloma immunity. Together, the immune system critically acts as a rheostat that fine-tunes the balance between dormancy and disease progression in PC dyscrasias.
引用
- Nakamura K, Smyth MJ, Martinet L, et al. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood. 2020. PMID: 32645135. doi:10.1182/blood.2020006540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。